title: Liquid oral suspension adefovir dipivoxil (GS-02-526): an update on treatments for hepatitis B infection.
abstract: Though the global epidemiology of hepatitis B virus infection has declined due to effective immunization, chronic hepatitis B (CHB) remains a serious public health problem and there is still a need for more treatment options that are efficient, safe and simple for different kinds of CHB patients. Adefovir dipivoxil (ADV) liquid suspension (GS-02-526), as a new form of oral ADV, not only has competent antiviral efficacy, but is also more convenient for patients with swallowing difficulties or patients with impaired renal function requiring dosage adjustment. The clinical data evaluating the safety, tolerability and antiviral activity of liquid suspension of ADV as well as its tablet are summarized in this article. The availability of liquid oral suspension of ADV would allow more patients to receive timely and reasonable antiviral treatments.
authors.affiliation: Center of Infectious Diseases, West China Hospital of Sichuan University, No. 37 Guo Xue Xiang, Chengdu 610041, China.
authors.forename: En-Qiang
authors.initials: EQ
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Shi
authors.forename: Dong-Bo
authors.initials: DB
authors.lastname: Wu
authors.forename: Hong
authors.initials: H
authors.lastname: Tang
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000097:blood; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D013535:Suspensions; D000225:Adenine; C106812:adefovir dipivoxil
keywords: adefovir dipivoxil; antiviral therapy; chronic hepatitis B; hepatitis B virus; oral suspension